Latest filings (excl ownership)
25-NSE
Exchange delisting
6 Sep 24
8-K
VBI Vaccines Provides an Update on its Restructuring Proceedings
2 Aug 24
8-K
VBI Vaccines Initiates Restructuring Proceedings Under CCAA to Implement a Review of its Strategic Alternatives
30 Jul 24
8-K
VBI Vaccines Announces Results of Annual General Meeting
25 Jun 24
8-K
VBI Vaccines Announces New Tumor Response Data from Ongoing Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent Glioblastoma Patients
29 May 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
24 May 24
8-K
VBI Vaccines Reports First Quarter 2024 Financial Results
15 May 24
424B5
Prospectus supplement for primary offering
15 May 24
10-Q
2024 Q1
Quarterly report
15 May 24
8-K
Other Events
1 May 24
ARS
2023 FY
Annual report to shareholders
29 Apr 24
DEFA14A
Additional proxy soliciting materials
29 Apr 24
DEF 14A
Definitive proxy
29 Apr 24
10-K
2023 FY
Annual report
16 Apr 24
8-K
VBI Vaccines Reports Full Year 2023 Financial Results
16 Apr 24
8-K
VBI Vaccines Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
11 Apr 24
424B5
Prospectus supplement for primary offering
11 Apr 24
8-K
VBI Vaccines Presents Encouraging Early Tumor Response Data From Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent Glioblastoma
3 Apr 24
8-K
VBI Vaccines Announces Expanded Strategic Partnership with Canadian Government to Advance mRNA-Launched eVLP (MLE) Vaccine Platform
2 Apr 24
NT 10-K
Notice of late annual filing
28 Mar 24
8-K
VBI Announces Agreement to Sell Manufacturing Capabilities, Certain Related Assets, and Enter Into New License Agreement with Brii Biosciences
14 Feb 24
8-K
Entry into a Material Definitive Agreement
6 Feb 24
8-K
Entry into a Material Definitive Agreement
23 Jan 24
8-K
Entry into a Material Definitive Agreement
11 Jan 24
8-K
Entry into a Material Definitive Agreement
26 Dec 23
8-K
Entry into a Material Definitive Agreement
12 Dec 23
8-K
Entry into a Material Definitive Agreement
29 Nov 23
8-K
Regulation FD Disclosure
20 Nov 23
8-K
VBI Vaccines Reports Third Quarter 2023 Financial Results
14 Nov 23
10-Q
2023 Q3
Quarterly report
14 Nov 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
3 Nov 23
8-K
VBI Vaccines Expands Proprietary Technology Platforms With Development of a Novel mRNA-Launched eVLP Vaccine Program
26 Oct 23
8-K
Regulation FD Disclosure
27 Sep 23
8-K
VBI Vaccines Announces Dosing of First Patients in Phase 2b Study of VBI-1901 in Recurrent GBM
7 Sep 23
8-K
Regulation FD Disclosure
6 Sep 23
10-Q
2023 Q2
Quarterly report
14 Aug 23
8-K
VBI Vaccines Reports Second Quarter 2023 Financial Results
14 Aug 23
8-K/A
Submission of Matters to a Vote of Security Holders
27 Jul 23
8-K
VBI Vaccines Announces Closing of Underwriters’ Partial Exercise of Option to Purchase Additional Common Shares
24 Jul 23
8-K
VBI Vaccines Announces PreHevbri® is Now Available in the Netherlands and Belgium for the Prevention of Hepatitis B in Adults
19 Jul 23
Latest ownership filings
SC 13D/A
PERCEPTIVE ADVISORS LLC
17 Apr 24
SC 13D/A
PERCEPTIVE ADVISORS LLC
20 Nov 23
4
Michel DeWilde
31 Jul 23
4
Damian Braga
31 Jul 23
4
Jeff Baxter
28 Jul 23
4
Joanne Cordeiro
28 Jul 23
4
Nell Beattie
28 Jul 23
4
VAUGHN B HIMES
28 Jul 23
4
Avi Mazaltov
28 Jul 23
4
Francisco Diaz-Mitoma
28 Jul 23
4
STEVEN GILLIS
28 Jul 23
4
John Robert Dillman
28 Jul 23
4
Blaine H. McKee
28 Jul 23
4
David Evander Anderson
28 Jul 23
SC 13G
Brii Biosciences Ltd
20 Jul 23
4
STEVEN GILLIS
18 Jul 23
4
VAUGHN B HIMES
28 Apr 23
3
VAUGHN B HIMES
25 Apr 23
SC 13D/A
PERCEPTIVE ADVISORS LLC
7 Apr 23
4
JOSEPH EDELMAN
6 Apr 23
SC 13G
BlackRock Inc.
6 Apr 23
SC 13G/A
BlackRock Inc.
1 Feb 23
4
Avi Mazaltov
30 Jan 23
4
Michel DeWilde
30 Jan 23
4
STEVEN GILLIS
30 Jan 23
4
Joanne Cordeiro
30 Jan 23
4
John Robert Dillman
30 Jan 23
4
Jeff Baxter
30 Jan 23
4
Damian Braga
30 Jan 23
4
David Evander Anderson
30 Jan 23
4
Francisco Diaz-Mitoma
30 Jan 23
4
Nell Beattie
30 Jan 23
4
Christopher McNulty
30 Jan 23
4
Blaine H. McKee
30 Jan 23
4
John Robert Dillman
12 Jul 22
3
John Robert Dillman
12 Jul 22
SC 13G/A
STATE STREET CORP
10 Feb 22
SC 13G/A
BlackRock Inc.
1 Feb 22
4
Michel DeWilde
31 Jan 22
4
Christopher McNulty
31 Jan 22